Eloralintide is one of the newest obesity drugs to move from an obscure development code into mainstream peptide discussion. Also called LY3841136, LY-3841136, AMY1176, or simply Elora, it is Eli Lilly's investigational, long-acting selective amylin-receptor agonist.
It is not a GLP-1 drug. It does not activate the same combination of receptors as tirzepatide or retatrutide. Instead, eloralintide is designed to use an amylin pathway involved in satiety and food intake.
The interest is not based only on animal research. A 48-week randomized Phase 2 trial reported estimated mean weight reductions of approximately 9% to 20%, depending on the regimen, compared with 0.4% for placebo. Lilly has since moved eloralintide into a broad Phase 3 program.
That makes eloralintide scientifically important. It does not make research-market vials an approved treatment or establish that products sold online are equivalent to Lilly's clinical material.
Elora versus GLP-1s and retatrutide
The simplest way to understand Elora is by what it targets. Semaglutide and tirzepatide use incretin pathways. Retatrutide combines three metabolic receptor targets. Eloralintide uses the amylin pathway instead.
| Compound | Main receptor targets | What makes it different | Current US status |
|---|---|---|---|
| Eloralintide (Elora) | Preferential amylin 1 receptor agonist | Aims at amylin signaling involved in satiation and food intake | Investigational; Phase 3 |
| Semaglutide | GLP-1 receptor agonist | Single-incretin drug with approved diabetes and weight-management products | FDA-approved for specific indications |
| Tirzepatide | GIP and GLP-1 receptor agonist | Dual-incretin drug with approved diabetes and weight-management products | FDA-approved for specific indications |
| Retatrutide | GIP, GLP-1, and glucagon receptor agonist | Investigational triple agonist acting through three metabolic pathways | Investigational; Phase 3 |
That does not establish that Elora is better than a GLP-1 drug or retatrutide. There is no completed head-to-head human trial answering that question, and results from separate trials cannot be compared as though the participants and methods were identical.
The different mechanism does make combination research plausible. Lilly's ENLIGHTEN-6 Phase 3 trial is studying eloralintide in people who still have obesity while being treated with a weekly incretin medicine. That makes add-on therapy a legitimate clinical research question, but it is not evidence supporting self-directed stacking; results are not yet available.
For a deeper explanation of the triple agonist, see What Is Retatrutide?.
What the amylin pathway does
Amylin is a peptide hormone normally co-secreted with insulin by pancreatic beta cells after eating. It participates in the signaling that helps the brain register satiation and regulates processes including food intake, gastric emptying, and post-meal glucagon release.
An agonist activates a receptor. An amylin-receptor agonist attempts to reproduce selected parts of amylin signaling for longer than native amylin remains active.
Eloralintide was engineered as a long-acting peptide with preferential activity at the amylin 1 receptor, or AMY1R. Lilly's discovery work compared its receptor activity and pharmacology with other amylin-pathway peptides, including pramlintide and cagrilintide.
The word selective matters. Amylin-family compounds can activate overlapping combinations of amylin and calcitonin receptors. Eloralintide was designed to favor AMY1R rather than act as a broadly nonselective agonist. The hypothesis is that receptor selectivity may preserve useful appetite and body-weight effects with a different tolerability profile.
That is a development hypothesis, not a proven clinical advantage. There is no completed human head-to-head trial showing that eloralintide is safer or more effective than cagrilintide.
Eloralintide Phase 2 results
The central human evidence comes from a 48-week, randomized, double-blind, placebo-controlled Phase 2 trial conducted at 46 research centers in the United States.
The trial enrolled 263 adults with obesity, or overweight plus at least one weight-related condition, who did not have type 2 diabetes. Participants received a once-weekly subcutaneous injection of placebo or one of six eloralintide regimens.
The table reports the publication's efficacy-estimand results. These are modeled estimates intended to describe the effect if participants adhered to treatment; they should not be confused with guaranteed individual outcomes.
| Weekly trial regimen | Estimated mean weight change at 48 weeks |
|---|---|
| Placebo | -0.4% |
| Eloralintide 1 mg | -9% |
| Eloralintide 3 mg | -12% |
| Eloralintide 6 mg | -18% |
| Eloralintide 9 mg | -20% |
| Escalation from 6 mg to 9 mg | -20% |
| Escalation from 3 mg to 9 mg | -16% |
All six eloralintide groups met the trial's primary endpoint of superior weight reduction versus placebo. The dose-response pattern is one reason the results attracted attention.
The trial still has important limitations:
- The individual treatment groups were small, ranging from 24 to 54 participants.
- The study excluded people with type 2 diabetes, so the results do not answer every intended-use population.
- Eli Lilly funded the study, and several authors were affiliated with the developer.
- Forty-eight weeks is useful for detecting weight change but not enough to establish multi-year safety, durability, or cardiovascular outcomes.
- The results describe a controlled investigational product and monitored trial—not research-vendor vials.
Side effects and tolerability
The most common adverse events in Phase 2 were nausea and fatigue. Their frequency varied sharply across doses and escalation schedules.
Nausea ranged from 11% to 64% among the fixed-dose and escalation groups, versus 14% with placebo. Fatigue ranged from 0% to 46%, versus 12% with placebo. Those uneven rates are one reason it is more accurate to present the regimen-level data than claim eloralintide has universally mild side effects.
Lilly emphasized the lower-dose 3 mg group because it produced approximately 12% estimated weight loss with nausea similar to placebo. Higher-dose and faster-start groups generally produced more weight reduction, but some also had substantially more nausea or fatigue.
The study was not powered to detect uncommon harms. Phase 3 will provide a much larger safety dataset and will test different populations and clinical contexts.
Eloralintide versus cagrilintide
Eloralintide and cagrilintide belong to the same broad amylin-drug category, but they are not the same peptide and do not have identical receptor profiles.
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It has been studied alone and in combination with semaglutide. Eloralintide was designed by Lilly as a more AMY1R-selective agonist.
Preclinical comparisons are useful for understanding receptor pharmacology. They cannot prove that one compound will produce better weight loss, fewer side effects, or better long-term outcomes in people. No completed human head-to-head trial establishes eloralintide as a replacement for cagrilintide.
The Phase 3 ENLIGHTEN program
Eloralintide moved into Phase 3 after the 2025 Phase 2 readout. The current program examines more than a single general-obesity population.
| Trial | Population or research question | Current status |
|---|---|---|
| ENLIGHTEN-1 | Obesity or overweight without type 2 diabetes | Phase 3, recruiting |
| ENLIGHTEN-2 | Obesity or overweight with type 2 diabetes | Phase 3, recruiting |
| ENLIGHTEN-3 | Obesity and obstructive sleep apnea | Phase 3 program |
| ENLIGHTEN-4 | Obesity or overweight with osteoarthritis knee pain | Phase 3 program |
| ENLIGHTEN-6 | Persistent obesity during weekly incretin treatment | Phase 3, recruiting |
Primary completion dates for major ENLIGHTEN studies extend into 2028. Until those trials report, Phase 2 remains the main controlled efficacy evidence.
Is interest in eloralintide actually growing?
Yes, but from a very small base.
Google Trends showed almost no measurable United States search interest before Lilly's Phase 2 announcement in November 2025. Interest rose during spring 2026, reached its 12-month normalized peak in July, and remained near 70% of that peak during the week of August 9.
The related searches "eloralintide peptide" and "eloralintide vs retatrutide" were both classified as breakout queries. The shortened term "Elora peptide" had much less search interest, while LY3841136 produced too little data for a meaningful standalone trend.
This does not mean eloralintide is already comparable with retatrutide in public demand. In a direct 12-month Trends comparison, eloralintide averaged less than 1 relative-interest point while retatrutide averaged 59. The opportunity is its rate of growth and early research interest, not large established volume.
Can you buy Elora or eloralintide now?
There is no FDA-approved commercial eloralintide medicine. Research vendors advertising Elora or eloralintide are selling independently sourced research material, not Lilly's clinical-trial product.
On August 13, 2026, PeptidePrices checked its tracked vendor catalog for all three common identifiers:
- eloralintide
- Elora
- LY3841136
Only Purgo Labs had a confirmed live listing. NeuroLabs, Chameleon Peptides, Amino Club, and the other checked tracked vendors did not list it.
Purgo advertised a 5 mg vial for $69.99. Its posted Freedom Diagnostics certificate for lot PL-EL5-01 reported:
- LC-MS identity: Eloralintide
- HPLC-UV purity: 99.05%
- Measured net content: 4.80 mg
That certificate is useful batch evidence. It also illustrates why the measured amount matters alongside the label: the tested vial contained 4% less peptide than the nominal 5 mg.
One listing is not a price comparison. PeptidePrices is waiting until at least five tracked vendors carry the compound before publishing a dedicated multi-vendor comparison page. That avoids presenting a single-store listing as if it were a functioning market.
What a vendor COA can and cannot establish
A certificate reporting a matching mass and a high-purity chromatogram provides evidence about the submitted sample. It does not establish that every vial in inventory is identical.
For a newly synthesized, structurally modified peptide, the strongest documentation should address several different questions:
- Identity: Is the measured molecular mass consistent with eloralintide?
- Purity: What proportion of the detected material is the intended principal compound?
- Amount: Does the measured net peptide content match the vial label?
- Batch linkage: Does the lot on the report match the vial being sold?
- Contamination controls: Were endotoxin, sterility, or other relevant risks tested separately?
HPLC purity by itself cannot establish complete sequence, structural arrangement, sterility, or clinical equivalence. Even an LC-MS identity result applies to the submitted sample and the analytical method used.
Our guide to verifying peptide COAs explains how to separate a useful batch report from a generic certificate.
Is eloralintide FDA-approved?
No.
Eloralintide appears in FDA's substance-registration system under UNII 73G3354J8W, with LY3841136 and AMY1176 recorded as synonyms. The database itself warns that receiving a UNII does not imply regulatory review or approval.
Recruiting Phase 3 trials also do not constitute approval. Lilly must complete the necessary studies, submit a marketing application, and receive an FDA decision before an approved eloralintide medicine can be sold in the United States.
Bottom line
Eloralintide is a credible late-stage obesity-drug candidate, not just a newly marketed research peptide.
Its mechanism is different from GLP-1 and triple-agonist drugs. The 48-week Phase 2 trial produced meaningful, dose-dependent weight reduction, while also showing that nausea and fatigue can vary considerably by regimen. A multi-study Phase 3 program is now testing broader populations and add-on use with incretin treatment.
Search interest and research-market availability are beginning to move. They remain early. Only one PeptidePrices-tracked vendor currently lists the compound, which is below the threshold for an honest comparison page.
The appropriate conclusion today is straightforward: eloralintide deserves attention and evidence-based coverage, but it remains investigational, unapproved, and incompletely characterized.
Primary sources and current records
- Frias et al. Eloralintide 48-week Phase 2 trial, The Lancet, 2025.
- Briere et al. Eloralintide discovery and clinical proof of concept, 2025.
- Phase 2 ClinicalTrials.gov record NCT06230523.
- Lilly's Phase 2 results announcement, November 6, 2025.
- ENLIGHTEN-1 Phase 3 record NCT07321886.
- ENLIGHTEN-2 Phase 3 record NCT07282600.
- ENLIGHTEN-6 Phase 3 record NCT07392190.
- FDA substance record for eloralintide.
- Google Trends: eloralintide, United States, past 12 months.
- Purgo Labs Elora listing and its linked Freedom Diagnostics batch certificate, checked August 13, 2026.
This article is educational and does not provide medical advice, dosing instructions, or a recommendation to use an investigational compound. Research-market products are not equivalent to Lilly's clinical-trial material.